189 filings
Page 5 of 10
8-K
gix6s3d7jv2l kil
25 Feb 19
Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
8:51am
8-K
ch59q svf
15 Feb 19
Marker Therapeutics Announces Change in Corporate Headquarters and Access to New Laboratory Facility
4:55pm
8-K
n6fov9
15 Jan 19
Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
5:15pm
8-K
gg867
4 Jan 19
Marker Therapeutics Provides Updates of its Lead Clinical Programs
12:34pm
8-K
o9l7tz d2ekhu
4 Dec 18
Other Events
12:00am
8-K
ymkhi9
3 Dec 18
Departure of Directors or Certain Officers
4:12pm
8-K
blvwsa pzvc75
27 Nov 18
The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting
4:58pm
8-K
smv3t6w0e0pmrrca78b
27 Nov 18
Marker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer
9:15am
8-K
3850f
30 Oct 18
Other Events
4:18pm
8-K/A
qh2a3n9
29 Oct 18
Financial Statements and Exhibits
12:00am
8-K
qbwlzzxmpiigsr1zjbj
23 Oct 18
Marker Therapeutics, Inc. Announces New Executive Appointments
5:08pm
8-K
aa86daocza6
17 Oct 18
Tapimmune and Marker Therapeutics Announce Successful Closing of Previously Announced Merger and Financing
4:00pm
8-K
ti2zef7rwj4q
8 Aug 18
Other Events
4:40pm
8-K
xxqdq68413cxpq9igxy
8 Jun 18
TapImmune Announces Pricing of $70 Million Private Placement
9:21am
8-K
me5n 9x4p
18 May 18
Entry into a Material Definitive Agreement
5:16pm
8-K
8nvq3quz q94k
15 May 18
TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
6:07am
8-K
gahgv5m1 pt
25 Sep 17
TapImmune Appoints Peter Hoang as President and Chief Executive Officer
12:00am
8-K
4oe7406
5 Sep 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
4j5 vrpmbr
11 Jul 17
Departure of Directors or Certain Officers
12:00am
8-K
o8upro
26 Jun 17
Unregistered Sales of Equity Securities
12:00am